Document is current
Any future updates will be listed below
-
Authors
Hota, Swetansu K. https://orcid.org/0000-0003-3105-9729
Rao, Kavitha S.
Blair, Andrew P.
Khalilimeybodi, Ali https://orcid.org/0000-0001-9318-8433
Hu, Kevin M. https://orcid.org/0000-0001-5513-7854
Thomas, Reuben
So, Kevin https://orcid.org/0000-0002-5193-7384
Kameswaran, Vasumathi https://orcid.org/0000-0003-2552-6183
Xu, Jiewei
Polacco, Benjamin J. https://orcid.org/0000-0003-1570-9234
Desai, Ravi V. https://orcid.org/0000-0002-0336-0883
Chatterjee, Nilanjana https://orcid.org/0000-0002-1203-5222
Hsu, Austin
Muncie, Jonathon M. https://orcid.org/0000-0002-7405-6213
Blotnick, Aaron M. https://orcid.org/0000-0001-8646-6853
Winchester, Sarah A. B.
Weinberger, Leor S.
Hüttenhain, Ruth
Kathiriya, Irfan S. https://orcid.org/0000-0003-1207-1490
Krogan, Nevan J.
Saucerman, Jeffrey J.
Bruneau, Benoit G. https://orcid.org/0000-0002-0804-7597
- License Information
-
More Information
Article History
Received: 15 May 2020
Accepted: 8 December 2021
First Online: 26 January 2022
Competing interests
: B.G.B. is a co-founder and shareholder of Tenaya Therapeutics and consults for and has equity in Silvercreek Pharmaceuticals. The work presented here is not related to the interests of Tenaya Therapeutics or Silvercreek Pharmaceuticals. The Krogan laboratory has received research support from Vir Biotechnology and F. Hoffmann-La Roche. N.K. has consulting agreements with the Icahn School of Medicine at Mount Sinai, New York, Maze Therapeutics and Interline Therapeutics, is a shareholder of Tenaya Therapeutics and has received stocks from Maze Therapeutics and Interline Therapeutics. The other authors declare no competing interests.
